

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L1 and glucocerebrosidase	6

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L3

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** **Monday, April 08, 2002** [Printable Copy](#) [Create Case](#)**Set Name Query**

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ

<u>L3</u>	L1 and glucocerebrosidase	6	<u>L3</u>
<u>L2</u>	L1 with glucocerebrosidase	0	<u>L2</u>
<u>L1</u>	ht-1080	153	<u>L1</u>

END OF SEARCH HISTORY

WEST



Generate Collection

Print

L3: Entry 1 of 6

File: USPT

Jun 19, 2001

DOCUMENT-IDENTIFIER: US 6248319 B1

TITLE: Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides

Detailed Description Paragraph Right (30):

SCF is useful for expanding early hematopoietic progenitors in syngeneic, allogeneic, or autologous bone marrow transplantation. The use of hematopoietic growth factors has been shown to decrease the time for neutrophil recovery after transplantation Donahue, et al., Nature, 321, 872-875 (1986) and Welte et al., J. Exp. Med., 165, 941-948, (1987)]. For bone marrow transplantation, the following three scenarios are used alone or in combination: a donor is treated with SCF alone or in combination with other hematopoietic factors prior to bone marrow aspiration or peripheral blood leucophoresis to increase the number of cells available for transplantation; the bone marrow is treated in vitro to activate or expand the cell number prior to transplantation; finally, the recipient is treated to enhance engraftment of the donor marrow. SCF is useful for enhancing the efficiency of gene therapy based on transfecting (or infecting with a retroviral vector) hematopoietic stem cells. SCF permits culturing and multiplication of the early hematopoietic progenitor cells which are to be transfected. The culture can be done with SCF alone or in combination with IL-6, IL-3, or both. Once tranfected, these cells are then infused in a bone marrow transplant into patients suffering from genetic disorders. [Lim, Proc. Natl. Acad. Sci, 86, 8892-8896 (1989)]. Examples of genes which are useful in treating genetic disorders include adenosine deaminase, glucocerebrosidase, hemoglobin, and cystic fibrosis.

Detailed Description Paragraph Right (311):A. Construction of the HT-1080 cDNA LibraryDetailed Description Paragraph Right (312):

Total RNA was isolated from human fibrosarcoma cell line HT-1080 (ATCC CCL 121) by the acid guanidinium thiocyanate-phenol-chloroform extraction method [Chomczynski et al., Anal. Biochem. 162, 156 (1987)], and poly(A) RNA was recovered by using oligo(dT) spin column purchased from Clontech. Double-stranded cDNA was prepared from 2 .mu.g poly(A) RNA with a BRL (Bethesda Research Laboratory) cDNA synthesis kit under the conditions recommended by the supplier. Approximately 100 ng of column fractionated double-stranded cDNA with an average size of 2 kb was ligated to 300 ng SalI/NotI digested vector pSPORT 1 [D'Alessio et al., Focus, 12, 47-50 (1990)] and transformed into DH5.alpha. (BRL, Bethesda, Md.) cells by electroporation [Dower et al., Nucl. Acids Res., 16, 6127-6145 (1988)].

LOGINID:ssspta1800exs

Welcome to STN International! Enter x:
STNLOGON timed out

Commerical Database access on COM server not responding.

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 25 Searching with the P indicator for Preparations
NEWS 4 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 5 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 6 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 7 Mar 08 Gene Names now available in BIOSIS
NEWS 8 Mar 22 TOXLIT no longer available
NEWS 9 Mar 22 TRCTHERMO no longer available
NEWS 10 Mar 28 US Provisional Priorities searched with P in CA/CAPlus
and USPATFULL
NEWS 11 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 12 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 13 Apr 08 "Ask CAS" for self-help around the clock

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

*LBEILSTEIN - BEILSTEIN Learning File

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 17:50:55 ON 08 APR 2002

=> fil .eliz

COST IN U.S. DOLLARS

SINCE FILE

AL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 17:51:03 ON 08 APR 2002

FILE 'SCISEARCH' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 DERWENT INFORMATION LTD AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 17:51:03 ON 08 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 17:51:03 ON 08 APR 2002

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2002)

FILE 'ESBIOBASE' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 DERWENT INFORMATION LTD

=> s ht-1080

L1 3232 HT-1080

=> s l1 (5a) glucocerebrosidase

L2 1 L1 (5A) GLUCOCEREBROSIDASE

=>

=>

=>

=>

=>

=> d

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:157596 HCAPLUS

DN 136:199031

TI High mannose proteins and methods of making high mannose proteins

IN Kinoshita, Carol A.; Prashsant, Mishra; Borowski, Marianne;

Francis-Daniel, Peter

PA Transkaryotic Therapies, Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015927	A1	20020228	WO 2001-US25882	20010817
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-641471	A1	20000818		
RE.CNT	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> d ab

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS
AB The invention features a method of producing a high mannose glucocerebrosidase (hmGCB) which includes: providing a cell which is capable of expressing glucocerebrosidase (GCB), and allowing prodn. of GCB having a precursor oligosaccharide under conditions which prevent the removal of .gtoreq.1 mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB, to thereby produce an hmGCB prepn. Preferably, the condition which prevents the removal of .gtoreq.1 mannose residue distal to the pentasaccharide core is inhibition of a class 1 processing mannosidase and/or a class 2 processing mannosidase. The invention also features an hmGCB prepn. and methods of using an hmGCB prepn.

This invention

LOGINID:ssspta1800exs

Welcome to STN International! Enter x:
STNLOGON timed out

Commerical Database access on COM server not responding.

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 25 Searching with the P indicator for Preparations
NEWS 4 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 5 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 6 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 7 Mar 08 Gene Names now available in BIOSIS
NEWS 8 Mar 22 TOXLIT no longer available
NEWS 9 Mar 22 TRCTHERMO no longer available
NEWS 10 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS
and USPATFULL
NEWS 11 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 12 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 13 Apr 08 "Ask CAS" for self-help around the clock

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

*LBEILSTEIN - BEILSTEIN Learning File

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 17:50:55 ON 08 APR 2002

=> fil .eliz

COST IN U.S. DOLLARS

SINCE FILE

AL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 17:51:03 ON 08 APR 2002

FILE 'SCISEARCH' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 DERWENT INFORMATION LTD AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 17:51:03 ON 08 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 17:51:03 ON 08 APR 2002

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2002)

FILE 'ESBIOBASE' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:51:03 ON 08 APR 2002

COPYRIGHT (C) 2002 DERWENT INFORMATION LTD

=> s ht-1080

L1 3232 HT-1080

=> s l1 (5a) glucocerebrosidase

L2 1 L1 (5A) GLUCOCEREBROSIDASE

=>

=>

=>

=>

=>

=> d

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:157596 HCAPLUS

DN 136:199031

TI High mannose proteins and methods of making high mannose proteins

IN Kinoshita, Carol A.; Prashant, Mishra; Borowski, Marianne;

Francis-Daniel, Peter

PA Transkaryotic Therapies, Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015927	A1	20020228	WO 2001-US25882	20010817
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-641471 A1 20000818

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ab

L2 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS

AB The invention features a method of producing a high mannose glucocerebrosidase (hmGCB) which includes: providing a cell which is capable of expressing glucocerebrosidase (GCB), and allowing prodn. of GCB having a precursor oligosaccharide under conditions which prevent the removal of .gtoreq.1 mannose residue distal to the pentasaccharide core of the precursor oligosaccharide of GCB, to thereby produce an hmGCB prepn. Preferably, the condition which prevents the removal of .gtoreq.1 mannose residue distal to the pentasaccharide core is inhibition of a class 1 processing mannosidase and/or a class 2 processing mannosidase. The invention also features an hmGCB prepn. and methods of using an hmGCB prepn.

=> s l1 and glucocerebrosidase

L3 3 L1 AND GLUCOCEREBROSIDASE

=> dup rem l3

PROCESSING COMPLETED FOR L3

L4 3 DUP REM L3 (0 DUPLICATES REMOVED)

=> d 1-3

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:157596 HCAPLUS

DN 136:199031

TI High mannose proteins and methods of making high mannose proteins

IN Kinoshita, Carol A.; Prashsant, Mishra; Borowski, Marianne;

Francis-Daniel, Peter

PA Transkaryotic Therapies, Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015927	A1	20020228	WO 2001-US25882	20010817
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-641471 A1 20000818

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS REC
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS
AN 1997:425951 HCAPLUS
DN 127:91349
TI Protein production and protein delivery
IN Treco, Douglas A.; Heartlein, Michael W.; Selden, Richard F.
PA Transkaryotic Therapies, Inc., USA
SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 985,586, abandoned.
CODEN: USXXAM

DT Patent
LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5641670	A	19970624	US 1994-243391	19940513
	EP 750044	A2	19961227	EP 1996-202037	19921105
	EP 750044	A3	19970115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	US 6063630	A	20000516	US 1994-231439	19940420
	CN 1119545	A	19960403	CN 1994-107587	19940602
	US 5733746	A	19980331	US 1995-406030	19950317
	US 6270989	B1	20010807		
	CA 2190289	AA	19951123	CA 1995-2190289	19950511
	WO 9531560	A1	19951123	WO 1995-US6045	19950511
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9525504	A1	19951205	AU 1995-25504	19950511
	AU 709058	B2	19990819		
	EP 759082	A1	19970226	EP 1995-919831	19950511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	BR 9507874	A	19970819	BR 1995-7874	19950511
	HU 76844	A2	19971128	HU 1996-3144	19950511
	JP 10500570	T2	19980120	JP 1995-529826	19950511
	ZA 9503879	A	19960118	ZA 1995-3879	19950512
	US 6187305	B1	20010213	US 1995-446921	19950518
	US 6214622	B1	20010410	US 1995-446928	19950518
	US 6048524	A	20000411	US 1995-446909	19950522
	US 6048724	A	20000411	US 1995-446911	19950522
	US 5733761	A	19980331	US 1995-451893	19950526
	US 5968502	A	19991019	US 1995-451894	19950526
	FI 9604536	A	19970109	FI 1996-4536	19961112
	NO 9604802	A	19970109	NO 1996-4802	19961112
	US 6355241	B1	20020312	US 1999-420861	19991019
	AU 738395	B2	20010920	AU 1999-59536	19991118
	AU 9959536	A1	20000224		
PRAI	US 1991-787840	B2	19911105		
	US 1991-789188	B2	19911105		
	US 1992-911533	B2	19920710		
	US 1992-985586	B2	19921203		
	EP 1992-924367	A3	19921105		
	US 1994-231439	A3	19940420		
	US 1994-243391	A	19940513		
	US 1994-334455	A3	19941104		
	WO 1995-US6045	A	19950511		
	US 1995-446909	A1	19950522		

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS
AN 1996:58252 HCAPLUS
DN 124:78726
TI DNA construct for effecting homologous recombination and uses for recombinant protein production
IN Treco, Douglas A.; Heartlein, Michael W.; Selden, Richard F.

PA Transkaryotic Therapies, Inc. USA
 SO PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531560	A1	19951123	WO 1995-US6045	19950511
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5641670	A	19970624	US 1994-243391	19940513
	CN 1119545	A	19960403	CN 1994-107587	19940602
	AU 9525504	A1	19951205	AU 1995-25504	19950511
	AU 709058	B2	19990819		
	EP 759082	A1	19970226	EP 1995-919831	19950511
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	BR 9507874	A	19970819	BR 1995-7874	19950511
	JP 10500570	T2	19980120	JP 1995-529826	19950511
	FI 9604536	A	19970109	FI 1996-4536	19961112
	NO 9604802	A	19970109	NO 1996-4802	19961112
PRAI	US 1994-243391	A	19940513		
	US 1991-787840	B2	19911105		
	US 1991-789188	B2	19911105		
	US 1992-911533	B2	19920710		
	US 1992-985586	B2	19921203		
	WO 1995-US6045	A	19950511		

=> d 2,3 ab

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS
 AB The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within a cell. The homologously recombinant cell is then maintained under conditions which will permit transcription and translation, resulting in protein expression. The present invention further relates to homologously recombinant cells, including primary, secondary, or immortalized vertebrate cells, methods of making the cells, methods of homologous recombination to produce fusion genes, methods of altering gene expression in the cells, and methods of making a protein in a cell employing the constructs of the invention.

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS
 AB The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within the cell. The homologously recombinant cell is then maintained under conditions which will permit transcription and translation, resulting in protein expression. The present invention further relates to homologously recombinant cells, including primary, secondary, or immortalized vertebrate cells, methods of making the cells, methods of homologous recombination to produce fusion genes, methods of altering gene expression in the cells, and methods of making a protein in a cell employing the constructs of the invention.

=> d 2, 3 kwic

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2002 ACS
 IT Animal cell line

(HT-1080; protein prodn. protein delivery)

IT 9000-94-6, Antithrombin III 9001-24-5, Blood coagulation factor v
 9001-25-6, Blood coagulation factor vii 9001-28-9, Blood coagulation
 factor ix 9001-29-0, Blood coagulation factor x 9002-64-6, Parathyroid
 hormone 9002-72-6, Growth hormone 9003-98-9, Dnase 9004-10-8,
 Insulin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon,
 biological studies 9013-56-3, Blood coagulation factor xiii 9025-35-8,
 .alpha.-Galactosidase 9036-22-0, Tyrosine hydroxylase 9039-53-6,
 Urokinase 9041-92-3, .alpha.1-Antitrypsin 9054-89-1, Superoxide
 dismutase 9061-61-4, Nerve growth factor 11096-26-7, Erythropoietin
 12629-01-5, Human growth hormone 37228-64-1, **Glucocerebrosidase**
 61912-98-9, Insulin-like growth factor 83869-56-1, Granulocyte-
 macrophage colony-stimulating factor 118549-37-4, Insulinotropin
 139639-23-9, Tissue plasminogen activator 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (genes encoding; protein prodn. and protein delivery)

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2002 ACS

IT Animal cell line

(HT-1080, DNA construct for effecting homologous
 recombination and uses for recombinant protein prodn.)

IT 9000-94-6P, Antithrombin III 9001-24-5P, Blood coagulation factor V
 9001-25-6P, Blood coagulation factor Vii 9001-28-9P, Blood coagulation
 factor ix 9001-29-0P, Blood coagulation factor x 9002-64-6P,
 Parathyroid hormone 9002-72-6P, Somatotropin 9003-98-9P, Dnase
 9004-10-8P, Insulin, preparation 9007-12-9P, Calcitonin 9007-92-5P,
 Glucagon, preparation 9013-56-3P, Blood coagulation factor xiii
 9025-35-8P, .alpha.-Galactosidase 9036-22-0P, Tyrosine hydroxylase
 9039-53-6P, Urokinase 9041-92-3P, .alpha.1-Antitrypsin 9054-89-1P,
 Superoxide dismutase 9061-61-4P, Nerve growth factor 11096-26-7P,
 Erythropoietin 37228-64-1P, **Glucocerebrosidase** 61912-98-9P,
 Insulin-like growth factor 62683-29-8P, Csf 81627-83-0P, m-Csf
 113189-02-9P, Blood coagulation factor Viii 118549-37-4P, Insulinotropin
 139639-23-9P, Tissue plasminogen activator 141436-78-4P, Protein kinase
 c 143011-72-7P, g-CSF
 RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP
 (Preparation)

(DNA construct for effecting homologous recombination and uses for
 recombinant protein prodn.)

=> s kinoshita, ?/au

L5 48438 KINOSHITA, ?/AU

=> s l5 and glucocerebrosidase

L6 8 L5 AND GLUCOCEREBROSIDASE

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 2 DUP REM L6 (6 DUPLICATES REMOVED)

=> d 1,2

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:157596 HCAPLUS

DN 136:199031

TI High mannose proteins and methods of making high mannose proteins

IN **Kinoshita, Carol A.**; Prashsant, Mishra; Borowski, Marianne;
 Francis-Daniel, Peter

PA Transkaryotic Therapies, Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002015927	A1	20020228	WO 2001-US25882	20010817

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DM, DZ, EC, EE, ES, FI, GB, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-641471 A1 20000818

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 MEDLINE DUPLICATE 1
 AN 96061066 MEDLINE
 DN 96061066 PubMed ID: 7576080
 TI Position of the sulfhydryl group and the disulfide bonds of human
glucocerebrosidase.
 AU Lee Y; Kinoshita H; Radke G; Weiler S; Barranger J A; Tomich J M
 CS Department of Pediatrics, University of Southern California Medical
 School, Childrens Hospital of Los Angeles, California 90027, USA.
 SO JOURNAL OF PROTEIN CHEMISTRY, (1995 Apr) 14 (3) 127-37.
 Journal code: AEJ; 8217321. ISSN: 0277-8033.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 199511
 ED Entered STN: 19960124
 Last Updated on STN: 19960124
 Entered Medline: 19951128

=> dis his

(FILE 'HOME' ENTERED AT 17:50:55 ON 08 APR 2002)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS,
 NTIS, ESBIODASE, BIOTECHNO, WPIDS' ENTERED AT 17:51:03 ON 08 APR 2002

L1 3232 S HT-1080
 L2 1 S L1 (5A) GLUCOCEREBROSIDASE
 L3 3 S L1 AND GLUCOCEREBROSIDASE
 L4 3 DUP REM L3 (0 DUPLICATES REMOVED)
 L5 48438 S KINOSHITA, ?/AU
 L6 8 S L5 AND GLUCOCEREBROSIDASE
 L7 2 DUP REM L6 (6 DUPLICATES REMOVED)

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	28.16	28.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.86	-1.86

SESSION WILL BE HELD FOR 60 MINUTES